Episode Details

Moderna’s new mRNA flu shot, mFlusiva, is poised to revolutionize flu protection for seniors—potentially faster to adapt to viral changes and offering strong antibody responses. After a rocky start with FDA scrutiny over study comparisons, Moderna pushed back with supporting data, including a smaller trial showing antibody levels rivaling the gold-standard high-dose vaccine. Still, gaps remain for the most vulnerable elderly. The FDA advisory panel’s verdict could be the make-or-break moment before flu season hits.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/5addb69f66f1de76